Brantley Kristen D, Kirkner Gregory J, Hughes Melissa E, Varella Leticia, Suggs Georgia, Cunningham Olivia M, Ravikumar Sanjana, Snow Craig, Tolaney Sara M, Sammons Sarah, Partridge Ann H, Lin Nancy U
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Medicine, Harvard School of Medicine, Boston, MA, USA.
NPJ Breast Cancer. 2025 Aug 29;11(1):96. doi: 10.1038/s41523-025-00822-y.
The influence of young age at diagnosis on prognosis of patients with metastatic breast cancer (MBC) remains unclear. We examined overall survival (OS) within a single-institution prospective study of patients with de novo or recurrent MBC. Kaplan-Meier curves assessed OS by age (≤35 or ≤40 years as the youngest category) and inferred metastatic tumor subtype. Multivariable Cox regression models estimated hazard ratios (HRs) and 95% CIs for OS by age adjusting for clinical factors. Of 4189 women <75 years, 571 were ≤40 years at MBC diagnosis, of whom 260 were ≤35 years. Over half (52%) died during follow-up (median = 5.3 years, IQR = 2.1-9.8 years). Compared to patients 45-55 years, those ≤35 years at diagnosis experienced worse OS (HR = 1.22, 95%CI 1.00-1.48, p = 0.05). This association was driven by HER2-negative/luminal B-like and hormone receptor-positive/HER2-positive tumors. These findings highlight the need to develop more effective therapies for young patients with this metastatic subtype.
诊断时年龄较轻对转移性乳腺癌（MBC）患者预后的影响仍不清楚。我们在一项针对初发或复发性MBC患者的单机构前瞻性研究中考察了总生存期（OS）。Kaplan-Meier曲线按年龄（将≤35岁或≤40岁作为最年轻类别）和推断的转移性肿瘤亚型评估OS。多变量Cox回归模型通过对临床因素进行校正，估计年龄对OS的风险比（HR）和95%置信区间（CI）。在4189名年龄小于75岁的女性中，571名在MBC诊断时年龄≤40岁，其中260名年龄≤35岁。超过一半（52%）的患者在随访期间死亡（中位数=5.3年，四分位间距=2.1-9.8年）。与45-55岁的患者相比，诊断时年龄≤35岁的患者OS较差（HR=1.22，95%CI 1.00-1.48，p=0.05）。这种关联由HER2阴性/管腔B样和激素受体阳性/HER2阳性肿瘤驱动。这些发现凸显了为患有这种转移性亚型的年轻患者开发更有效治疗方法的必要性。
Cochrane Database Syst Rev. 2014-6-12
JAMA. 2024-1-16
Front Endocrinol (Lausanne). 2023
Arch Pathol Lab Med. 2023-9-1
PET Clin. 2023-10
Zotero 插件